Effects of a novel hepatitis B anti-viral drug E-CFCP in renal organic acid transporters
Currently, the emergence of drug resistance is an important issue in the treatment of hepatitis B virus (HBV). Recently, our collaborating group developed a novel long-acting anti-HBV drug, E-CFCP. However, until this study, the effects of E-CFCP in the kidney have remained unclarified. Using cell v...
Saved in:
Main Authors: | Misaki Ishibane (Author), Hirofumi Hashimoto (Author), Meika Kaneko (Author), Shota Saito (Author), Sangjon Pae (Author), Shinpei Saito (Author), Yoshie Reien (Author), Yuri Hirayama (Author), Nobuyo Higashi-Kuwata (Author), Hiroaki Mitsuya (Author), Naohiko Anzai (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2022-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Effects of islatravir (4'-ethynyl-2-fluoro-2'-deoxyadenosine or EFdA) on renal tubular cells and islatravir's interactions with organic anion transporters
by: Meika Kaneko, et al.
Published: (2021) -
Targeting L-type amino acid transporter 1 in urological malignancy: Current status and future perspective
by: Sangjon Pae, et al.
Published: (2022) -
JPH203, a newly developed anti-cancer drug, shows a preincubation inhibitory effect on L-type amino acid transporter 1 function
by: Kentaro Okunushi, et al.
Published: (2020) -
Differentiated HASTR/ci35 cells: A promising in vitro human astrocyte model for facilitating CNS drug development studies
by: Keita Kitamura, et al.
Published: (2018) -
L-type amino acid transporter 1 as a target for inflammatory disease and cancer immunotherapy
by: Keitaro Hayashi, et al.
Published: (2022)